TELA Bio, Inc.
TELA · XNASCIK 1561921fmd_1RDAGM12W4TXBZH9AHDW84WHKCManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 34 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 8 | 15 | 18 | 29 | 41 | 58 | 69 | 80 |
| Gross profit | 3 | 3 | 9 | 11 | 19 | 27 | 40 | 46 | 54 |
| Research and development | 6 | 4 | 4 | 4 | 7 | 9 | 10 | 9 | 9 |
| Selling, general and administrative | 14 | 19 | 24 | 32 | 42 | 57 | 75 | 79 | 79 |
| Total operating expenses | 19 | 21 | 28 | 37 | 48 | 66 | 84 | 88 | 88 |
| Operating income | (17) | (18) | (19) | (25) | (29) | (39) | (44) | (34) | (34) |
| Interest expense | 5 | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
| Other non-operating income (expense) | (4) | (3) | (3) | (4) | (4) | (5) | (3) | (4) | (5) |
| Income before taxes | – | – | – | – | – | (44) | (47) | (38) | (39) |
| Income tax expense | – | – | – | – | – | – | – | (0) | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (38) | (39) |
| Net income | (21) | (21) | (22) | (29) | (33) | (44) | (47) | (38) | (39) |
| Net income to common shareholders | (27) | (30) | (30) | (29) | (33) | – | – | – | – |